Video Journal of Dementia (VJDementia)

Introducing: Video Journal of Dementia (VJDementia) 🧠 Welcome! 👋 💜 The Video Journal of Dementia is a global, open access, expert-led video journal, bringing healthcare professionals trustworthy, cutting-edge updates in #Dementia in an accessible manner 🔦 We will be posting regular updates on here, sharing podcasts, feature articles, congress coverage & MORE so give us a follow 📲 In the meantime, here are some fantastic resources you can find on our site: 🗞️ Feature Articles - quick-to-read updates on the latest data, as well as presentations and slides from specialist meetings https://lnkd.in/dUAwvf7i 🏥 Disease areas we cover including #Alzheimersdisease, #LewyBodyDementia, #Frontotemporaldementia, #Vasculardementia https://lnkd.in/dWi_G5Yn 🔬 Filter by topic area, including #Diagnostics, #Biology, #Biomarkers, #Treatment, #Clinicalcare, #Prevention https://lnkd.in/d4aRf3xv 🎧 VJDementia Podcast - the latest #Dementia updates on your favourite podcast platform https://lnkd.in/dxHkz92u 📩 Our VJDementia Newsletter - receive the latest #Dementia updates via email https://lnkd.in/ddf2MAGP 🌐 https://lnkd.in/ddKaT2jn 🌐 #Alzheimers #Parkinsons #Frontotemporaldementia #VascularDementia #LewyBodyDementia #dementiaawareness

Join us for our upcoming webinar: 'Translating Novel Diagnostics into Practice: Updates for #NeurodegenerativeDiseases' 🧠 📣 🗓️ 4 November 2024 ⏰ 9:00-11:00 CST / 15:00-17:00 GMT / 16:00-18:00 CET 💬 Chaired by Prof. Charlotte Teunissen Co-moderated by Dr Nicholas Ashton, Prof. Stephen Salloway & Prof. Malú Gámez Tansey Agendas will be available closer to the time 📝 REGISTER 👉 https://lnkd.in/g_cVKJ5R #Neurology #VJNeurology #Neurologywebinar #Neurologynews

📣 We are excited to announce the launch of Magdalen Scientific, the events arm of Magdalen Medical Publishing. 💬 Magdalen Scientific is dedicated to organizing high-quality events, including face-to-face scientific workshops and virtual educational webinars. 🎥 With our world-leading video journals including the Video Journal of Hematology & Hematological Oncology (VJHemOnc), Video Journal of Oncology (VJOncology) Video Journal of Neurology (VJNeurology), we bring the same level of excellence to our events. 🌐 Visit our new website to learn more about our upcoming events: magdalenscientific.com #MagdalenScientific #IME #HCPEducation #scientificworkshops #educationalwebinars #VJHemOnc #VJOncology #VJNeurology

#FDA grants approval to anti-#amyloid #monoclonalantibody #donanemab for the treatment of #Alzheimersdisease 🧠 🗞️ On July 2, 2024, the U.S. Food and Drug Administration (FDA) approved #donanemab-azbt (Kisunla) for the treatment of #Alzheimersdisease (AD) based on evidence of clinically meaningful benefit in the Phase III #TRAILBLAZER-ALZ 2 trial The disease-modifying agent is available as an intravenous infusion for patients with mild cognitive impairment (MCI) due to AD We also spoke with Marwan Sabbagh, MD, Cleveland Clinic Lou Ruvo Center for Brain Health, at the AD/PD™ 2021 conference, who delved deeper into the mechanism of #anti-#amyloid #monoclonalantibodies. He highlighted, ‘We clearly think that the production and presence of #amyloid drives other changes in the #brain: #synapse loss, #cytotoxicity, #inflammation, #tau spread, etc. So, a lot of people have said “lets target #amyloid” because it makes sense to remove’ 🎥 💬 Find out more about #Donanemab, the TRAILBLAZER-ALZ 2 trial, access and implications & MORE 👉 https://lnkd.in/ebR-BPsC #Dementia #Alz #Dementianews

Check out our NEW #podcast: Exploring plasma p-tau217: a game-changer in #Alzheimer’s trials 🎧 🧠 In this episode, we dive into the latest advancements in Alzheimer’s disease (AD) #biomarkers, focusing on the #diagnostic and #predictive potential of #plasma #ptau217 As an alternative to traditional PET assessment, #blood-based #biomarker detection has the potential to provide a time-efficient, cost-effective strategy for pre-#screening and treatment monitoring in AD #clinicaltrials 🩸 Although the widespread use of blood-based #biomarkers in clinical practice remains to be seen, they also hold promise in expediting diagnostic/prognostic procedures for AD We are joined by renowned researchers: 🌟 Marco Bucci, PhD, Karolinska Institutet 🌟 Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine 🌟 Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh 🌟 Lyduine Collij, PhD, Lund University Give it a listen 👉 https://lnkd.in/eAgG--TD Use the time codes to skip to your favourite part of each episode 👀 SUBSCRIBE so you don't miss any future episodes📱 #VJDementia #Dementianews

#FDA approves #benzgalantamine for symptomatic relief of mild-to-moderate #Alzheimer’s disease with reduced side effects 🧠 🗞️ Considered a new-generation AChEI, it is hoped its reduced side effect profile will enable more patients to tolerate treatment 💡 “The approval of #ZUNVEYL is a pivotal moment in the fight against #Alzheimersdisease as it is only the second oral AD treatment to be approved in more than a decade. #ZUNVEYL was designed to addresses a critical need for a tolerable and effective treatment that can potentially enhance patients’ daily lives with improved long-term outcomes” - Michael Mcfadden, Chief Executive Officer, Alpha Cognition, Inc. Find out more 👉 https://lnkd.in/eAvDuqz4 #Dementia #Alz #Dementianews

🚀 Launching our new website! 🚀 🎉 Magdalen Medical Publishing is proud to present our new platform dedicated to medical events, Magdalen Scientific. 🎥 With established video journals like Video Journal of Hematology & Hematological Oncology (VJHemOnc), Video Journal of Oncology (VJOncology) and Video Journal of Neurology (VJNeurology), we bring the same level of excellence to our events. Discover more about our events and how to partner with us, by visiting our new website: magdalenscientific.com   #MagdalenScientific #IME #HCPEducation #scientificworkshops #educationalwebinars #VJHemOnc #VJOncology #VJNeurology

NEW from #CONy2024 | Barriers to #dementia treatment: awareness, #accessibility, and #affordability 🎥 🧠 Paola Barbarino, MA, CEO of Alzheimer's Disease International, raises concerns about the awareness, accessibility, and affordability of new disease-modifying therapies, namely anti-amyloid medications 🔦 High costs may prevent reimbursement for those who could benefit. Even before considering treatment costs, global #diagnostic capabilities represent a huge barrier, with many #healthcare systems lacking the resources and trained #clinicians for accurate and timely diagnosis 🩺 💵 Ms Barbarino highlights the scarcity of medical professionals who recognize #dementia as a disease, citing the 2019 World Alzheimer’s Report where 62% of respondents did not view dementia as a disease, but a normal part of aging 💡 The lack of understanding extends beyond the general public, affecting #medical communities and contributing to the stigma surrounding #dementia Learn more 👉 https://lnkd.in/esXphr3N #VJDementia

At the 18th Annual Congress on Controversies in Neurology (CONy 2024) ADI CEO Paola Barbarino discussed with Video Journal of Dementia (VJDementia) about investment in #dementia and Alzheimer's disease therapeutics. She also expressed concerns that patients are being denied their human right to make informed decisions about their treatment options due to access issues. As populations age, dementia is set to become an even more significant health challenge and is currently the 7th leading cause of death globally. #DementiaTreatments #TimeToActOnDementia #WhatsYourPlan #ADI 

📣We are excited to announce the launch of Magdalen Scientific, the events arm of Magdalen Medical Publishing. 💬Magdalen Scientific is dedicated to organizing high-quality events, including face-to-face scientific workshops and virtual educational webinars. 🩺 Our goal is to create opportunities for scientific exchange and best-practice sharing amongst HCPs. 🌐 Visit our new website to learn more about our upcoming events: magdalenscientific.com #MagdalenScientific #IME #HCPEducation #scientificworkshops #educationalwebinars #VJHemOnc #VJOncology #VJNeurology